Cancer Antigen 125
Also known as: CA125
Use
The Cancer Antigen 125 test is used to evaluate and monitor ovarian cancer, particularly the epithelial subtype. It aids in monitoring the response to therapy for patients with epithelial ovarian cancer. Serial testing is recommended in conjunction with other clinical methods for monitoring ovarian cancer.
Special Instructions
The test is not recommended for monitoring breast cancer or germ tumors and should not be used as a stand-alone test for ovarian cancer screening or diagnosis.
Limitations
Patients with confirmed ovarian carcinoma may have pretreatment CA 125 values in the same range as healthy individuals. Elevated levels of CA 125 may also be observed in patients with nonmalignant diseases. Therefore, a CA 125 value, regardless of the level, should not be interpreted as absolute evidence of the presence or absence of malignant disease. Moreover, results obtained with different test methods or kits cannot be used interchangeably.
FDA ApprovedNew York Approved
Methodology
Immunoassay (ECLIA)
Biomarkers
LOINC Codes
- 10334-1
- 10334-1
Result Turnaround Time
1 day
Related Documents
For more information, please review the documents below
Specimen
Plasma
Volume
1 mL
Minimum Volume
0.5 mL
Container
Plasma separator tube or serum separator tube. Also acceptable: Green (lithium heparin), lavender (EDTA), or pink (K2EDTA, K3EDTA).
Collection Instructions
Allow specimen to clot completely at room temperature. Separate serum or plasma from cells ASAP or within 2 hours of collection. Transfer to an ARUP Standard Transport Tube.
Causes for Rejection
Grossly hemolyzed specimens.
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 5 days |
| Refrigerated | 5 days |
| Frozen | 24 weeks |